Breadcrumb

Breadcrumbs

Phase 3 Oncology Compounds main Article

Other Late-Stage Programs

Phase 3 Oncology Compounds-Timeline

Pexidartinib

CSF-1R Inhibitor

Pexidartinib (formerly known as PLX3397) is an investigational oral selective inhibitor of CSF-1R in phase 3 development for tenosynovial giant cell tumor (TGCT), which includes pigmented villonodular synovitis (PVNS) and giant cell tumor of the tendon sheath (GCT-TS). TGCT is a rare, usually non-cancerous tumor that affects the synovium-lined joints, bursae, and tendon sheaths.

Pexidartinib has been granted Orphan Drug Designation and Breakthrough Therapy Designation by the FDA for the treatment of TGCT. It also has received Orphan Drug Designation from EMA for the treatment of TGCT.

For more information about the phase 3 ENLIVEN study, visit ClinicalTrials.gov.

Patritumab

HER3 Inhibitor

Patritumab is an investigational fully human HER3-targeting monoclonal antibody in phase 2 clinical development as part of a combination therapy for recurrent or metastatic head and neck cancer.

For more information about this phase 2 study, visit ClinicalTrials.gov.

Oncology more stories content

More Stories

Daiichi Sankyo Cancer Enterprise

The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer.

read more ...

Other Late-Stage Programs content

These compounds are investigational agents and are not approved by the FDA or other regulatory agencies worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There is no guarantee that these compounds will become commercially available in indications under investigation.